<DOC>
	<DOCNO>NCT01644500</DOCNO>
	<brief_summary>The purpose study examine once-weekly dulaglutide efficient safe compare glimepiride participant type 2 diabetes mellitus inadequate glycemic control oral antihyperglycemic medication ( OAM ) OAM-naïve .</brief_summary>
	<brief_title>A Study Comparing Effects Safety Dulaglutide With Glimepiride Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Type 2 diabetes mellitus OAMnaïve take OAM monotherapy least 3 month Glycosylated Hemoglobin ( HbA1c ) value ≥7.0 % ≤10.5 % OAMnaïve participant ≥6.5 % ≤10.0 % participant take OAM monotherapy Adult men adult nonpregnant , nonbreastfeeding woman Stable weight ( ±5 % ) ≥3 month prior screen Body mass index ( BMI ) ≥19.0 ≤35.0 kilogram per square meter ( kg/m^2 ) Have type 1 diabetes mellitus Have previously treat glucagonlike peptide1 ( GLP1 ) receptor agonist , GLP1 analog , incretin mimetic 3 month screen Are currently take dipeptidylpeptidaseIV ( DPPIV ) inhibitor thiazolidinediones ( TZD ) 3 month screen Have gastric empty abnormality Have cardiac disorder define unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention , heart failure , arrhythmia , transient ischemic attack , stroke Have poorly control hypertension ( systolic blood pressure 160 millimeter mercury [ mmHg ] diastolic blood pressure 95 mmHg ) Have impair liver function Have impair kidney function Have history chronic pancreatitis acute pancreatitis Have serum calcitonin ≥20 picogram/milliliter ( pg/mL ) Have personal family history medullary Ccell hyperplasia , focal hyperplasia , carcinoma multiple endocrine neoplasia type 2 ( MEN 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>